期刊文献+

原发性血小板增多症患者血栓事件发生情况及影响因素分析

Anaysis on the Occurrence of Thrombotic Events and Influencing Factors in Patients with Essential Thrombocythemia
下载PDF
导出
摘要 目的分析原发性血小板增多症(ET)患者血栓事件的发生情况及其影响因素。方法回顾性分析2019年1月至2021年1月我院收治的86例ET患者的临床资料,统计患者血栓事件发生情况,采用单因素和多因素分析找出影响ET患者发生血栓事件的相关因素。结果86例ET患者中,28例发生血栓事件,占32.56%。ET患者血栓事件的发生可能受其年龄、既往血栓史、合并高血压、WBC、JAK2V617F突变的影响(P<0.05);多因素Logistic分析结果显示,年龄、既往血栓史、合并高血压、WBC、JAK2V617F突变是ET患者发生血栓事件的影响因素(P<0.05)。结论ET患者血栓事件的发生与其年龄、既往血栓史、合并高血压、WBC、JAK2V617F突变等因素密切相关,临床需对上述影响因素重点关注。 Objective To analyze the occurrence of thrombotic events in patients with essential thrombocythemia(ET)and its influencing factors.Methods The clinical data of 86 patients with ET admitted to our hospital from January 2019 to January 2021 were retrospectively analyzed.The occurrence of thrombotic events in patients was counted.Univariate analysis and multivariate analysis were used to find out the related factors affecting the occurrence of thrombotic events in ET patients.Results Of the 86 ET patients,28 had thrombotic events,accounting for 32.56%.The occurrence of thrombotic events in ET patients may be affected by their age,previous history of thrombosis,hypertension,WBC,and JAK2V617F mutation(P<0.05).Multivariate Logistic analysis showed that age,previous history of thrombosis,hypertension,WBC and JAK2V617F mutation were the influencing factors for the occurrence of thrombotic events in ET patients(P<0.05).Conclusions The occurrence of thrombotic events in ET patients is closely related to their age,previous history of thrombosis,hypertension,WBC,and JAK2V617F mutation,which need to be paid attention to in clinical practice.
作者 仝佳音 杨学文 赵小强 刘静静 TONG Jiayin;YANG Xuewen;HAXiooqiang;LIU Jinging(Department of Hematology.the First Affilited Hospital of He'nan Universily of Science and Technology,Luoyang 471000,China)
出处 《临床医学工程》 2023年第6期871-872,共2页 Clinical Medicine & Engineering
关键词 原发性血小板增多症 血栓事件 影响因素 Essential thrombocythemia Thrombotic events Influencing factors
  • 相关文献

参考文献8

二级参考文献60

  • 1卓家才,刘焕勋,蔡力生,游伟文,蔡云,汪鹏程,杜新,陈俊雄,汪明春.原发性血小板增多症按危险度分层治疗及效果[J].广东医学,2004,25(8):933-934. 被引量:5
  • 2Tefferi A,Vardiman J W.Classification and diagnosis of myeloproliferative neoplasms:The 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J].Leukemia,2008,22(1):14-22.
  • 3Baxter E J,Scott L M,Campbell P J,et al.Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders[J].Lancet,2005,365(9464):1054-1061.
  • 4Xia L,Ding K Y,Cai X Y,et al.Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm[J].Zhonghua Xue Ye Xue Za Zhi,2010,31 (9):590-593.
  • 5Rosti V,Bonetti E,Bergamaschi G,et al.High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis[J].PLoS One,2010,5(12):e152.
  • 6Harrison C N,Green A R.Essential thrombocythaemia[J].Clin Haematol,2006,19(3):439-453.
  • 7Kralovics R, Passamonti F, Buser AS, et a|. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005, 352(17)1779-1790.
  • 8Palandri F, Polverelli N, Catani I., et al. Impact of leukocytosison thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol, 2011, 90(8) :933-938.
  • 9Tefferi A, Vardiman JW. myeloproliferative neoplasm Organization criteria and po Leukemia, 2008, 22(1) :14 2 Classification and diagnosis of s : the 2008 World Health int of-care diagnostic algorithms. 2.
  • 10Levine LR, Gilliland DG. Myeloproliferative disorders. Blood, 2008(112) :2190-2197.

共引文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部